Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | IGF2R | P11717 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AMY2A | P04746 | 2/20 | 0.37 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.37 |
| ▸ | GJB2 | P29033 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138503 | 0.89 | SELP (0.38) | CA2GJB2 | |
| SCHEMBL14231358 | 0.86 | CA2 (0.35) | CA2GAAGJB2 | |
| SCHEMBL4594969 | 0.86 | CA2 (0.35) | CA2GAAGJB2 | |
| SCHEMBL4594966 | 0.86 | CA2 (0.35) | CA2GAAGJB2 | |
| SCHEMBL13447456 | 0.82 | CA2 (0.48) | CA2GAACDK1CCNB1IGF2R | |
| SCHEMBL12508190 | 0.82 | CA2 (0.50) | CA2GAACDK1CCNB1IGF2R | |
| SCHEMBL13424104 | 0.82 | CA2 (0.50) | CA2GAACDK1CCNB1IGF2R | |
| SCHEMBL12418558 | 0.82 | CA2 (0.50) | CA2GAACDK1CCNB1IGF2R | |
| SCHEMBL13932836 | 0.81 | CA2 (0.55) | CA2GAACDK1CCNB1IGF2R | |
| SCHEMBL14925477 | 0.79 | GAA (0.48) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310912-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2013-11-21 | — | — | US | disclosed |
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | CA2 320/4885GAA 1209/4885CDK1 4002/4885 |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | CA2 320/4885GAA 1209/4885CDK1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.